ION expands ETF trading capabilities with Tradeweb integration
Decheng Capital China Life Sciences USD Fund III, L.P. sold 11,772 shares of BeyondSpring Inc. (NASDAQ:BYSI), a $67.35 million market cap biotech company, between September 22 and September 24, 2025, for approximately $20,752. The shares were sold in multiple transactions at prices ranging from $1.68 to $1.83, with the stock currently trading at $1.69. According to InvestingPro analysis, BYSI maintains a healthy balance sheet with more cash than debt.
The sales were executed in three separate transactions. On September 22, 2025, 5,410 shares were sold at a weighted average price of $1.83. On September 23, 2025, 4,106 shares were sold at a weighted average price of $1.72. Finally, on September 24, 2025, 2,256 shares were sold at a weighted average price of $1.68. The company maintains a strong liquidity position with a current ratio of 2.19.
Following the transactions, Decheng Capital China Life Sciences USD Fund III, L.P. directly holds 1,847,561 shares. Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares, and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares. Get deeper insights into BYSI’s financial health metrics and 7 additional key ProTips with InvestingPro.
In other recent news, BeyondSpring Inc . announced positive results from a clinical study involving its lead drug, Plinabulin. The study, published in Med (Cell Press), demonstrated that Plinabulin, when used in combination with radiation and checkpoint inhibitors, showed efficacy in patients who had previously not responded to immune checkpoint inhibitor (ICI) therapy. Specifically, the Phase 1 trial achieved a 23% objective response rate and a 54% disease control rate in non-irradiated lesions among evaluable ICI-relapsed patients. Additionally, BeyondSpring has scheduled its 2025 annual shareholder meeting for September 15, 2025. The record date for the meeting is set for July 25, 2025, with shareholder proposals due by July 14, 2025. Proposals must adhere to Rule 14a-8 of the Securities Exchange Act to be considered for inclusion in the proxy statement. These developments reflect BeyondSpring’s ongoing efforts in both clinical advancements and corporate governance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.